Most men should have a conversation about prostate cancer screening starting at age 50. If you’re at higher risk, that conversation should happen earlier, between ages 40 and 50. The screening itself is straightforward: a blood test that measures a protein called PSA, sometimes paired with a physical exam. But when to start, how often to repeat it, and when to stop all depend on your individual risk profile.
Screening Age by Risk Level
For men at average risk who are expected to live at least 10 more years, the American Cancer Society recommends discussing screening at age 50. “Discussing” is the key word here. Unlike some cancer screenings that have a clear-cut recommendation, prostate screening is treated as a shared decision between you and your doctor because the test can lead to both benefits and real downsides.
If you’re Black or African American, guidelines recommend starting the conversation earlier, between ages 45 and 50. Black men develop prostate cancer at higher rates and tend to be diagnosed at more advanced stages, which is why earlier and potentially more frequent screening is recommended for this group.
Men with a first-degree relative (father or brother) who had prostate cancer should also consider screening between ages 40 and 54, according to Johns Hopkins Medicine. The closer the relative and the younger they were at diagnosis, the more reason to start earlier. Having multiple close relatives with prostate cancer pushes the recommended starting age even lower in that 40 to 54 window.
What the Screening Involves
Prostate screening today centers on a PSA blood test. PSA is a protein produced by the prostate, and elevated levels can signal cancer, though they can also rise from non-cancerous conditions like an enlarged prostate or an infection. The traditional threshold that triggers further investigation is 4.0 ng/mL, but what counts as “normal” actually shifts with age. Reference ranges developed for white American men set the upper limits at 2.5 ng/mL for men in their 40s, 3.5 ng/mL in their 50s, 4.5 ng/mL in their 60s, and 6.5 ng/mL in their 70s.
The digital rectal exam, where a doctor physically feels the prostate through the rectum, is the test most people picture when they hear “prostate exam.” It’s still used, but its role has shifted. Research shows that the PSA blood test is highly sensitive (catches most cancers) but not very specific (flags many men who don’t have cancer). The physical exam is less sensitive but better at correctly identifying who actually has cancer. When combined, the two tests together reach about 91% accuracy, significantly outperforming either test alone. Your doctor may use one or both depending on your situation.
How Often to Get Screened
After your first PSA test, the follow-up schedule depends on your results. If your PSA level is low, you may not need another test for two years or longer. If your level is higher or you have other risk factors, annual testing is more common. The American Urological Association’s updated guidelines, amended in 2025, emphasize that re-screening intervals should be personalized based on your PSA level, age, overall health, and cancer risk.
One useful benchmark: men aged 70 to 74 who have been screened previously and have a PSA below 3.0 ng/mL have very low rates of dying from prostate cancer (around 0.1% to 0.85% by age 85, depending on their exact PSA level). For these men, stopping screening altogether is a reasonable option.
When Screening Stops Making Sense
The U.S. Preventive Services Task Force recommends against routine PSA screening for men 70 and older. The reasoning is practical: prostate cancer typically grows slowly, and the time it takes for screening to produce a survival benefit often exceeds the remaining life expectancy of older men. Meanwhile, the risks of false positives, unnecessary biopsies, and overtreatment continue to climb with age.
That said, the cutoff isn’t absolute. The AUA’s 2025 update acknowledges that men between 70 and 80 may still benefit from screening in certain cases, particularly if they’re in excellent health and have had prior elevated PSA results. The decision should weigh the realistic chance of catching a dangerous cancer against the risk of finding a slow-growing one that would never cause harm.
The Overdiagnosis Problem
The reason prostate screening guidelines are more cautious than, say, colon cancer screening comes down to overdiagnosis. Studies estimate that 22% to 67% of cancers found through PSA screening would never have caused symptoms or death if left undetected. These are typically small, slow-growing tumors that a man would live with, not die from.
The trouble is that once cancer is found, most men choose treatment. Data from U.S. registries shows that about 55% of men with low-risk prostate cancer undergo surgery or radiation, even when their cancer may never progress. Among men 55 and younger with very low-risk disease, that number jumps to 96%. In Sweden, where active surveillance (monitoring without immediate treatment) is more culturally accepted, 59% of men with very low-risk cancer chose monitoring over treatment.
This doesn’t mean screening is bad. It means the value of screening depends heavily on what happens after a positive result. If an elevated PSA leads to a biopsy that finds low-risk cancer, active surveillance is a legitimate option that avoids the side effects of surgery or radiation while keeping close tabs on any changes. Understanding this ahead of time helps you make a better decision about whether to start screening in the first place.
What This Means for You
If you’re in your 40s with a family history of prostate cancer or you’re Black, bring up screening with your doctor now. If you’re at average risk, age 50 is the time. The first step is a simple blood draw, not the physical exam most men dread. Your initial PSA number will set the baseline for how often you’re tested going forward and whether additional evaluation is needed.
If you’re over 70 and have been screened regularly with low PSA results, stopping screening is a reasonable and evidence-supported choice. If you’re over 70 with higher PSA levels or other concerns, continued screening can still be discussed, but the balance of benefit and harm shifts significantly at that age.